Bioveta secures more double-digit growth through vaccine sales
Not only did the firm celebrate its 100th anniversary in 2018 but it also posted an 11% year-on-year improvement in revenues to €65.9 million ($76 million). This growth was all achieved organically.
Bioveta's core focus is veterinary vaccines, although it does manage a small human health portfolio. However, the company's marketing and sales director Marek Vystavěl told Animal Pharm: "Human health is included too but it is just a small fraction of the total sales. The main driver for the growth is the animal health part."
"Regions contributing to the growth the most were western Europe and southeastern Asia," stated the Ivanovice na Hané-headquartered business. "Bioveta plans to expand its sales activities especially in western Europe, Russia, China, and Latin America in the coming years. Increased investments in marketing are also accompanied by recruitment of marketing and sales specialists," said Marek Vystavěl.
Read more at Animal Pharm's article.